Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 4D Molecular Therapeutics Inc FDMT

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular... see more

Recent & Breaking News (NDAQ:FDMT)

4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS

GlobeNewswire 10 days ago

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

GlobeNewswire November 14, 2024

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

GlobeNewswire November 13, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Accesswire November 4, 2024

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire November 3, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Accesswire November 2, 2024

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire October 31, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Accesswire October 30, 2024

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire October 29, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Accesswire October 28, 2024

Shareholders Are Encouraged To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire October 27, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Accesswire October 26, 2024

Shareholders Are Encouraged To Join An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire October 25, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Accesswire October 24, 2024

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire October 23, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Accesswire October 22, 2024

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire October 21, 2024

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Accesswire October 20, 2024

Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations

Accesswire October 19, 2024

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Accesswire October 18, 2024